Matrix-Bound Nanovesicles from In Vitro Cell-Derived Extracellular Matrix Sheets

Tech ID: 34743 / UC Case 2026-802-0

BACKGROUND

Extracellular vesicles (EVs) are small membrane-bound vesicles released by most cells. They serve as key mediators of cell-to-cell communication and have shown utility in diagnostic and therapeutic applications. A novel class of EVs, similar in size to EVs derived from liquids (urine, blood, cell culture media, etc.), has been discovered natively embedded within the extracellular matrix of soft tissues and in vitro cell sheets. These matrix-bound nanovesicles (MBVs) reveal a potential novel mechanism of cell-environment interactions. Despite their promise as immunomodulatory therapies, MBVs remain critically understudied. They have yet to be isolated from stem cells and characterized for markers and qualities, and it remains unclear whether they are characteristically different from other matrix-resident vesicles such as matrix vesicles and migrasomes.

DESCRIPTION

Researchers at the University of California, Santa Barbara have created a novel method to isolate and confirm the presence of matrix-bound nanovesicles (MBVs) naturally secreted and embedded within extracellular matrix produced by cells grown in vitro. Unlike commonly studied exosomes derived from body fluids or conditioned media, MBVs are trapped within the extracellular matrix deposited by high-density stem cell cultures and can be selectively released using enzymatic digestion and purified by size exclusion chromatography. The isolated MBVs exhibit distinct size, surface proteins, and characteristics including enhanced CD63 expression and unique protein profiles compared to traditional extracellular vesicles. This technology enables detailed study and therapeutic exploitation of MBVs, which have demonstrated immunomodulatory potential and promise for tissue repair applications.

ADVANTAGES

- Defined markers and characteristics allow reliable identification and differentiation of MBVs from other EVs
- Maintains biological functionality relevant for immunomodulation and regenerative medicine
- Non-invasive, enzyme-based release method preserves vesicle integrity
- Applicable to human mesenchymal stem cell cultures, facilitating translational potential
- Enables specific isolation of MBVs embedded within in vitro cell-deposited extracellular matrix, distinct from exosomes

APPLICATIONS

- Regenerative medicine and tissue engineering therapies utilizing immunomodulatory MBVs

CONTACT

Donna M. Cyr
cyr@tia.ucsb.edu
tel: .

INVENTORS

- Dewey, Marley
- Dos Reis Marques, Renata

OTHER INFORMATION

KEYWORDS

vesicles, EVs, nanovesicles, matrix-bound nanovesicles, MBVs, exosomes, diagnostics, stem cell research, pharmaceuticals, biomaterials, drug delivery

CATEGORIZED AS

- **Medical**
  - Delivery Systems
  - Diagnostics
  - Stem Cell
  - Therapeutics

RELATED CASES

2026-802-0

- Development of novel diagnostics based on MBV surface markers and cargo
- Pharmaceuticals targeting cell-matrix interactions and extracellular vesicle-mediated signaling
- Stem cell research tools for extracellular matrix and vesicle biology
- Biomaterials and scaffold technologies incorporating MBVs for enhanced repair and healing
- Drug delivery by using MBVs as therapeutic carriers

ADDITIONAL TECHNOLOGIES BY THESE INVENTORS

- Controlled Release of Extracellular Vesicles by Alginate Biomaterials

University of California, Santa Barbara
Office of Technology & Industry Alliances
342 Lagoon Road, ,Santa Barbara,CA 93106-2055 |
https://www.tia.ucsb.edu
Tel: 805-893-2073 | Fax: 805.893.5236 | padilla@tia.ucsb.edu